Changeflow GovPing

What do you monitor?

Curated feeds for your role. Pick your area and get exactly the sources you need.

Recent changes

Favicon for www.courtlistener.com

State of Louisiana v. Sammy Cheatham - Sentencing Affirmation

The Louisiana Court of Appeal affirmed the sentences of Sammy Cheatham, who was convicted of attempted second-degree murder. The court noted a patent error in the sentencing, but the sentences were affirmed as imposed. Cheatham was sentenced to thirty years on each of seven counts, to run concurrently.

Priority review Enforcement Criminal Justice
3d ago CO PUC News
Favicon for puc.colorado.gov

Colorado PUC Announces April Public Comment and Engagement Opportunities

The Colorado Public Utilities Commission (PUC) has announced public comment and engagement opportunities for April 2026. Key events include public comment hearings for Atmos Energy's proposed gas rate increase (Proceeding No. 25AL-0499G), which seeks an approximate $17.56 million increase in annual base rate revenues.

Priority review Notice Utilities
Favicon for changeflow.com

USPTO Patent Application for Compounds Targeting Pax3/Foxo1 Fusion Protein

The USPTO has published patent application US20260083724A1, filed by Georgetown University, for novel compounds designed to target the PAX3::FOXO1 fusion protein. These compounds aim to reduce protein levels and treat fusion-positive rhabdomyosarcoma.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Patent Application: Sigmari Ligand for Pancreatic Cancer Treatment

The USPTO has published a patent application (US20260083725A1) for a Sigmari Ligand for the treatment of pancreatic cancer. The application details a method involving a Sig-1R ligand to inhibit tumor growth and metastasis, filed on August 9, 2023.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Cancer Treatment Methods Using Tumor Treating Fields, Chemotherapy, and Anti-Fibrotic Agents

The USPTO has published a patent application detailing methods for treating cancer. The application describes compositions and systems involving the concurrent application of tumor treating fields, chemotherapeutic agents, and anti-fibrotic agents to reduce cancer cell viability and tumor growth.

Routine Guidance Pharmaceuticals
Favicon for changeflow.com

Biopolymers for Ophthalmic Use Patent Application

The USPTO has published a patent application (US20260083771A1) for biopolymers intended for ophthalmic use, filed by ExoPolymer, Inc. The application details biopolymers comprising repeating polysaccharide units, their preparations, ophthalmic compositions, and methods of use.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Patent Application for Fiber-Based Prebiotic Dietary Supplements

The USPTO has published a patent application (US20260083772A1) for powder compositions comprising fiber intended for use as a prebiotic dietary supplement. The application details therapeutic ingredients and manufacturing processes aimed at improving gut microbiome and overall gut health.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Pegylated Menaquinol Compositions and Treatment Methods Patent Application

The USPTO has published a patent application (US20260083773A1) for pegylated menaquinol compositions and methods of treatment. The application, filed on December 5, 2025, discloses isolated, stable, and biologically active pegylated menaquinol derivatives for treating various diseases.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Patent Application: Acetic Acid and Hypochlorous Acid Compositions for Skin Trauma Treatment

The USPTO has published a new patent application (US20260083774A1) detailing compositions containing hypochlorous acid and acetic acid for treating skin trauma and biofilms. The application was filed on September 22, 2025, and published on March 26, 2026.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Metal nanoparticle agglomerates for infection control and water purification

The USPTO has published a patent application detailing the use of metal nanoparticle agglomerates for infection control and water purification. The application describes antiseptic substrates and fluid formulations incorporating these agglomerates for topical or oral use, aiming to provide infection control against infective agents.

Routine Guidance Pharmaceuticals

Showing 3831–3840 of 32,283 changes

1 382 383 384 385 386 3229

Get alerts when regulations change

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.